ClinicalTrials.gg
RecruitingNCT06184035TumoradUpdated Nov 20, 2025

A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer

A Phase 1/2 interventional study of [177Lu]Lu-SN201 in Solid Tumor, Metastatic Cancer and Unresectable Solid Tumor, sponsored by Spago Nanomedical AB. Recruiting at 2 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by Spago Nanomedical AB · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 260 studies in Neoplasm Metastasis with a site in Australia — 61 open to participants now, 106 under way, 34 of them phase 3. Neoplasm Metastasis · Australia.

Planned enrollment
181st of 253
90 · median 227
Started
2023
with 10 others
Phase 1/2
44 of 260
21 open now
Primary completion
2027-12
later than 65 of 105 live
Registered
217th of 260
by date

Among the 260 studies in Neoplasm Metastasis with a site in Australia, this one is the 181st largest by planned enrollment of the 253 interventional ones that give a count, is one of 11 that started in 2023, is one of 44 in phase 1/2, reaches primary completion later than 65 of the 105 other live ones, and was the 217th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

61 of the 260 studies in Neoplasm Metastasis with a site in Australia are open now. Recruiting first, the newest first:

56 more — sign in →

All 61 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 260 studies in Neoplasm Metastasis with a site in Australia, or all of them as a file.
02

Study summary

The purpose of this first-in-human (FIH) study is to determine the maximum tolerated dose (MTD) and to characterize the safety, tolerability, PK, and dosimetry profile of [177Lu]Lu-SN201 in adult participants with advanced solid tumors who have no standard of care treatment options.

[177Lu]Lu-SN201 is a radiolabeled, nanomedical investigational medicinal product (IMP) whose mechanism of delivery is based on the Enhanced Permeability and Retention (EPR) effect.

Read the detailed description

Eligible participants will receive [177Lu]Lu-SN201 via slow intravenous infusion on Cycle 1 Day 1. Participants will initially receive one cycle of treatment and will progress to a 2nd and 3rd cycle of treatment, provided retreatment criteria are met before the start of each cycle. The dosing schedule visit frequency will be every 6 weeks (with an allowable window to delay each cycle by +3 weeks per retreatment criteria), each participant may receive up to 3 cycles, with the treatment duration up to 22 weeks. A total of 3 treatment cycles will be given unless the participant meets early discontinuation criteria. For Cycle 1, an overnight hospitalization for standard-of-care observation following Day 1 clinic assessments to Day 2 is mandatory for all participants receiving Cycle 1.

Whole-body planar imaging, and single photon emission computed tomography (SPECT)/computed tomography (CT) will be performed post-administration of [177Lu]Lu-SN201 to assess biodistribution and dosimetry. CT or magnetic resonance imaging (MRI) will be used to assess the response of the disease to treatment using Response Evaluation Criteria (RECIST v1.1).

The general procedures for participants in Phase I and Phase IIa are summarized below:

  • Baseline values are defined as the last collected value prior to the start of infusion.
  • Continual assessment of adverse events (AEs) and concomitant medication usage will be conducted.
  • Whole-body planar on Day 1, Day 2, Day 4, and Day 8 and SPECT/CT on Day 2, Day 4 and Day 8 will be used for biodistribution and dosimetry evaluation of all participants. If dosimetry has been met by previous participants at each dose level, the DMC may partly or fully exclude the requirement for dosimetry procedures in remaining participants at this dose level.
  • For participants that will continue to treatment Cycle 2 or 3, eligibility assessment and IMP procurement will take place within the coming 17 days.
03

Conditions studied

  • Solid Tumor
  • Metastatic Cancer
  • Unresectable Solid Tumor
  • Recurrent Solid Tumor
  • Locally Advanced Solid Tumor
  • Refractory Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants ≥ 18 years of age on the day of signing .
  2. or cytologically documented, recurrent, locally advanced, or solid that has failed at least one prior systemic standard therapy, or for which standard therapy is not appropriate, or for which no standard therapy exists.
  3. (ECOG) performance status 0-2.
  4. ≥ 3 months.
  5. Adequate bone marrow, liver, and renal function, as assessed by the following laboratory requirements, to be conducted within 28 days before the start of the study IMP administration:

    1. ≥ 9.0 g/dL (transfusions are allowed).
    2. (ANC) ≥ 1500/mm3.
    3. count ≥ 100,000 mm3.
    4. Total ≤ 2.5 x (ULN) (in participants with liver metastases ≤ 5 ULN).
    5. (ALT) and aspartate transaminase (AST) ≤ 5 x ULN.
  6. On a stable dose of anti-coagulation therapy will be allowed to participate if they have no sign of bleeding or clotting and prothrombin/ and partial thromboplastin time (PT/INR and PTT, respectively) test results are compatible with the acceptable benefit-risk ratio at the Investigator's discretion.
  7. Serum creatinine ≤ 1.5 x ULN and estimated (eGFR) > 30 mL/min/1.73 m2 (per local values).
  8. use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    1. Male participants must agree to use a highly effective method of birth control as defined in ICH M3(R2) starting with the first dose of study medication through 120 days after the last dose of study medication.
    2. Female participants of * must have a negative pregnancy test documented at Screening and Baseline and be willing to use a highly effective method of contraception** or practice abstinence starting from ICF signature through to 120 days after the last dose of study medication.

      • A female of childbearing potential is a sexually mature female who 1) has not undergone a hysterectomy or bilateral oophorectomy, or 2) has not been naturally for at least 24 consecutive months (i.e., had had menses at any time in the preceding 24 consecutive months).

        • Effective contraception is defined as contraceptive methods with a failure rate of \< 1% to prevent pregnancy (combined [estrogen and progestogen containing] hormonal contraception associated with inhibition of ovulation [oral, intravaginal, transdermal], progestogen-only hormonal contraception associated with inhibition of ovulation [oral, injectable, implantable], intrauterine device [IUD] or intrauterine hormone-releasing system).
  9. Written informed consent to study participation.
  10. Be able to understand and comply with the requirements of the study, as judged by the Investigator.
  11. Phase I: At least one lesion as per v1.1.
  12. Phase IIa: At least one as per RECIST v1.1.

Exclusion criteria

Exclusion criteria:

  1. Unstable systemic disease (including but not limited to active infection, hepatic, renal, or metabolic disease).
  2. cardiac disease including any of the following:

    1. Congestive heart failure requiring treatment ( Grade ≥ 2).
    2. of \< 50%, as determined by MUGA or ECHO.
    3. Uncontrolled hypertension, defined as persistent systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg despite current therapy.
    4. History or presence of clinically significant ventricular arrhythmias or atrial fibrillation.
    5. Clinically significant resting bradycardia.
    6. Unstable angina pectoris ≤ 3 months before the start of study treatment.
    7. Acute myocardial infarction ≤ 3 months before the start of study treatment.
    8. Mean triplicate corrected for heart rate using Fridericia's formula (QTcF) value > 480 msec (as specified in Section 10.5).
  3. Known to pegylated drugs or vaccines (e.g., covid-19 vaccines).
  4. Concurrent or active solid or hematologic within the last 2 years with a distinct primary site or histology from the cancer being evaluated in this study except for the following cancer types: cervical cancer in situ, treated basal cell carcinoma, superficial bladder tumors (Ta and Tis).
  5. Infections not responding to therapy or active clinically serious infections.
  6. Known (HIV) infection, active virus (HBV), or virus (HCV) infection requiring treatment. Participants with chronic HBV or HCV infection are eligible at the Investigator's discretion provided that the disease is stable and sufficiently controlled under treatment.

    NB: Participants with may be included after discussion with Sponsor, except for the sentinel participants.

  7. Chemotherapy, experimental cancer therapy, biologic therapy, or immunotherapy within 2 weeks (or 5 half-lives, whatever is shortest) before the start of the study IMP administration.
  8. Palliative radiotherapy completed less than 2 weeks before the start of the study IMP administration will be allowed as long as no more than 10% of the participant's bone marrow was irradiated.
  9. Not recovered to Grade 1 from any prior anti-cancer therapy, excluding alopecia.
  10. Previous high-dose chemotherapy needing hemopoietin-stem-cell-rescue.
  11. Major surgery, open , or significant trauma within 4 weeks before the start of study treatment.
  12. A psychiatric or functional disorder that prevents participants from providing or following protocol instructions.
  13. A participant that has a condition or is in a situation, in the Investigator's opinion may put the individual at significant risk, may confound the study results, or may interfere significantly with their participation in the study.
  14. Is currently participating and receiving study therapy or has participated in a study of an agent and received study therapy or used an investigational device within 2 weeks or 5 half-lives of the agent, whichever is the shortest.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Phase I/IIa Dose escalation and dose expansion

    Participants will initially receive 1 cycle of \[177Lu\]Lu-SN201 via slow intravenous infusion and progress to up to 3 cycles, provided retreatment criteria are met before the start of each cycle, occurring every 6 weeks (with an allowable window to delay each cycle by +3 weeks per retreatment criteria). Dose escalation: The study will evaluate up to 5 dose levels of \[177Lu\]Lu-SN201 (A1=10 MBq/kg, A2=25 MBq/kg, A=50 MBq/kg, A4= \<33% of A3, A5= \<33% of A4). Additional dose levels may be explored until MTD/RP2D is identified. Up to 9 participants may be enrolled at any pre-specified dose level shown to be tolerated for confirmation of MTD and/or RP2D. Dose expansion: Once the MTD/RP2D has been defined, an expansion phase consisting of multiple tumor types, each with up to 20 participants, will be enrolled to further characterize the safety, tolerability, and assess preliminary efficacy of \[177Lu\]Lu-SN201 at the RP2D and/or MTD identified in Phase I.

    Drug: [177Lu]Lu-SN201

Interventions

06

What researchers measure

Primary outcomes

  1. Phase I/IIa: Frequency and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

    Clinically significant safety laboratory results will be graded by NCI CTCAE v5.0. AEs (including physical examination, vital signs, ECG, and safety lab findings), related AEs, DLTs, SAEs, and related SAEs, AEs with NCI CTCAE Grades ≥ 3, AEs leading to premature discontinuation, interruptions, duration of interruptions and discontinuation of IRP will be analyzed descriptively utilizing corresponding Medical Dictionary for Regulatory Activities System Organ Classes and Preferred Terms. NCI CTCAE v5.0 toxicity grades will be utilized for classifying severity. Continual assessment of adverse events (AEs) and concomitant medication usage will be conducted.

    Time frame: 48 months

  2. Phase I/IIa: Incidence of Dose-Limiting Toxicity (DLT) during the first cycle of treatment.

    DLTs are defined as: * Any Grade ≥ 3 AEs of any etiology that are clinically significant and last \> 7 days except: * Nausea, vomiting, or diarrhea will be considered a DLT only if it persists at Grade ≥ 3 for \> 3 days despite adequate supportive care measures. At the Investigator's discretion, participants who experience nausea, vomiting, or diarrhea after receiving IMP may receive antiemetic or anti-diarrheal medication before subsequent doses of IMP. * Isolated laboratory abnormalities Grade ≥ 3 (not present at Baseline) that are not considered to be significant by the Investigator and are resolved to at least Grade 1 within 7 days without clinical sequelae or need for therapeutic intervention. * Any other toxicity occurring at any time during the study that in the view of the participating Investigators and the Medical Monitor represents a clinically significant hazard to the participant. DLTs will be confirmed by the DMC.

    Time frame: 48 months

  3. Phase I: Dose escalation to identify RP2D and/or MTD dose

    RP2D and/or MTD will be based on the DLT rate. Dose escalation will follow BOIN design, directed by the DLT rate (the current number of participants with DLT divided by the current number of participants in the cohort). The study will evaluate up to 5 dose levels of \[177Lu\]Lu-SN201, however additional dose levels may be explored until MTD/RP2D is identified. If the starting dose is not tolerated, a lower dose may be evaluated based on toxicity, safety, pharmacokinetics, and dosimetry data as determined by the DMC.

    Time frame: 24 months

  4. Phase IIa: Clinical benefit in solid tumor subgroups at RP2D and/or MTD

    Clinical benefit according to RECIST v1.1 of \[177Lu\]Lu-SN201, as defined by post-treatment tumor response and serum levels of applicable tumor markers, compared to baseline (last collected value/measurement before the start of treatment)

    Time frame: 24 months

Secondary outcomes

  1. Phase I/IIa: Measure peak plasma [177Lu]Lu-SN201 activity concentration (Cmax)

    Characterize the pharmacokinetic Peak plasma concentration (Cmax) of the \[177Lu\]Lu-SN201 activity concentration over time

    Time frame: 48 months

  2. Phase I/IIa: Measure plasma half-life of the [177Lu]Lu-SN201 activity

    Characterize the pharmacokinetic half-life of the \[177Lu\]Lu-SN201 activity concentration over time in plasma

    Time frame: 48 months

  3. Phase I/IIa: Measure the area under the plasma concentration versus time curve (AUC) of [177Lu]Lu-SN201 activity

    Characterize the pharmacokinetic area under the curve vs time curve of the \[177Lu\]Lu-SN201 activity concentration in plasma over time

    Time frame: 48 months

  4. Phase I/IIa: Evaluation of clinical dosimetry

    To evaluate clinical dosimetry with whole-body planar and SPECT/CT imaging modalities to asses percentage injected dose of activity concentration and distribution of \[177Lu\]Lu-SN201 in tumor and organs.

    Time frame: 48 months

  5. Phase IIa: Evaluation of clinical benefit based on disease control rates (DCR)

    To evaluate clinical benefit based disease control rates (DCR) according to RECIST v1.1; * Overall Response Rate (ORR). * Duration of response (DoR). * Progression-free survival (PFS). * Overall survival (OS).

    Time frame: 12 months

Other outcomes

  1. Phase I: Evaluation of clinical benefit based on disease control rates (DCR)

    To evaluate clinical benefit based disease control rates (DCR) according to RECIST v1.1; * Overall Response Rate (ORR). * Duration of response (DoR). * Progression-free survival (PFS). * Overall survival (OS).

    Time frame: 12 months

  2. Phase I: Characterization of early signs of efficacy in tumor-type subgroups

    Up to 3 subgroups will be selected for the Phase IIa part of the study, based on emerging data on early signs of efficacy, and discussions with Clinical Investigators and Sponsor representatives.

    Time frame: 24 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2027, 47 months after the start.

Of 127 industry-sponsored phase 1/2 interventional studies under Neoplasm Metastasis, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 89. This study's planned 47 months is below that.

Counting every sponsor, half of 213 studies reached it within 62 months; a quarter within 41 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2023
First posted
Dec 28, 2023
StartActual
Dec 6, 2023
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06184035
Lead sponsor
Spago Nanomedical AB
Responsible party
Sponsor
First posted
Dec 28, 2023
Start date
Dec 6, 2023
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 20, 2025

Study contacts

Chief Development Officer
Contact
info@spagonanomedical.se
+46 46 81188
Kim Taubman
principal investigator · St Vincent Hospital Melbourne

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutetium-177

Start the discussion